Roche asks court for halt of Novartis unit’s generic launch

Roche’s subsidiary Genentech has asked a Delaware court to block two of Novartis’ units from selling a generic version of the blockbuster lung-disease drug Esbriet (pirfenidone).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Big Pharma

Novartis' Gilenya patent survives invalidity bid

12 May 2022 Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.

More on this story

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Big Pharma

Novartis' Gilenya patent survives invalidity bid

More on this story

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

Big Pharma

Roche and AstraZeneca units settle blood drug suit

17 February 2022 Roche’s Chugai and AstraZeneca’s Alexion Pharmaceuticals have brought their patent infringement dispute over a treatment for rare, fatal blood diseases to an end.

Big Pharma

Novartis' Gilenya patent survives invalidity bid